ストックスクリーナーアプリを入手
16.14
4.20%
0.65
アフターアワーズ：
16.14
前日終値:
$15.49
開ける：
$15.39
24時間の取引高:
249.91K
Relative Volume:
0.79
時価総額：
$299.64M
収益：
$62.81M
当期純損益:
$-13.75M
株価収益率:
-20.18
EPS:
-0.8
ネットキャッシュフロー:
$153.00K
1週間 パフォーマンス:
-8.24%
1か月 パフォーマンス:
+25.31%
6か月 パフォーマンス:
+179.24%
1年 パフォーマンス:
+88.55%
1日の値動き範囲:
$15.35
$16.49
1週間の範囲:
$15.10
$17.65
52週間の値動き範囲:
$3.78
$18.22
Optimizerx Corp Stock (OPRX) Company Profile
OPRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OPRX
Optimizerx Corp
|
16.14 | 315.23M | 62.81M | -13.75M | 153.00K | -0.80 |
|
VEEV
Veeva Systems Inc
|
282.28 | 46.10B | 2.86B | 780.66M | 1.19B | 4.72 |
|
TEM
Tempus Ai Inc
|
76.71 | 13.63B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
64.13 | 12.35B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
91.06 | 7.74B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
35.75 | 6.32B | 906.14M | -52.62M | 89.62M | -0.3621 |
Optimizerx Corp Stock (OPRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-08 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-12-20 | 開始されました | Stephens | Equal-Weight |
| 2024-07-25 | 再開されました | B. Riley Securities | Buy |
| 2024-04-04 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-01-03 | 開始されました | Barclays | Equal Weight |
| 2023-02-02 | 再開されました | B. Riley Securities | Buy |
| 2022-11-01 | 開始されました | Stifel | Buy |
| 2022-07-15 | 開始されました | SVB Leerink | Outperform |
| 2021-10-18 | 再開されました | B. Riley Securities | Buy |
| 2021-04-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2019-01-03 | 開始されました | William Blair | Outperform |
すべてを表示
Optimizerx Corp (OPRX) 最新ニュース
OptimizeRx Corp. (NASDAQ:OPRX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
OptimizeRx announces leadership reorganization to drive growth strategy - Investing.com
OptimizeRx Corp. Announces Leadership Changes to Enhance Growth Strategy and Profitability - Quiver Quantitative
OptimizeRx Corporation Announces Leadership Team Advancements to Accelerate Strategic Growth - MarketScreener
Major C-Suite Overhaul: OptimizeRx Names 6 Top Executives to New Roles in Healthcare Tech Growth Push - Stock Titan
OptimizeRx Corporation Attempts Reversal From Key SupportQuarterly Performance Summary & Reliable Entry Point Alerts - 선데이타임즈
Regression analysis insights on OptimizeRx Corporation performanceMarket Sentiment Summary & Accurate Buy Signal Alerts - Newser
How moving averages guide OptimizeRx Corporation tradingWeekly Profit Summary & Step-by-Step Swing Trade Plans - Newser
Short interest data insights for OptimizeRx CorporationGlobal Markets & Reliable Intraday Trade Plans - Newser
OptimizeRx Corp. (NASDAQ:OPRX) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
JMP Securities Forecasts Strong Price Appreciation for OptimizeRx (NASDAQ:OPRX) Stock - MarketBeat
Trend analysis for OptimizeRx Corporation this weekWeekly Profit Analysis & Verified Swing Trading Watchlists - Newser
Can you recover from losses in OptimizeRx Corporation2025 Key Lessons & Weekly High Potential Stock Alerts - Newser
Will breakout in OptimizeRx Corporation lead to full recoveryJuly 2025 PreEarnings & Capital Efficient Trade Techniques - Newser
What technical models suggest about OptimizeRx Corporation’s comebackForecast Cut & Stock Market Timing Techniques - Newser
OptimizeRx’s SWOT analysis: digital health firm’s stock faces scaling hurdles - Investing.com
OptimizeRx Reports 55% YoY Revenue Growth, Raises 2025 Guidance - AInvest
OptimizeRx (NASDAQ:OPRX) Given New $18.00 Price Target at Stifel Nicolaus - MarketBeat
OptimizeRx Corporation (NASDAQ:OPRX) Q2 2025 Earnings Call Transcript - Insider Monkey
Is OptimizeRx Corporation stock bottoming outTechnical Trend Forecast for Investors - Newser
OptimizeRX price target raised to $20 from $14 at JMP on strong earnings - Investing.com Nigeria
What makes OptimizeRx Corporation stock price move sharplySwing Trade Timing with Daily Forecast - Newser
Using AI based signals to follow OptimizeRx CorporationSteady Return Plan Based on Data Analysis - Newser
Should you hold or exit OptimizeRx Corporation nowTechnical Screener for High Growth Stocks - Newser
Blair William & Co. IL Buys 29,648 Shares of OptimizeRx Corp. (NASDAQ:OPRX) - MarketBeat
Applying Elliott Wave Theory to OptimizeRx CorporationShort Term Gain Strategy with AI Logic - Newser
OptimizeRx Corp. (OPRX) Surpasses Q2 Earnings and Revenue Estimates - MSN
Advanced analytics toolkit walkthrough for OptimizeRx CorporationTechnical Reversal Pattern Summary and Tracker - Newser
OptimizeRx Reports Strong Q2 2025 Financial Growth - The Globe and Mail
Healthcare Stocks Move in Friday's Pre-Market Session: OptimizeRx, Embecta, and More - AInvest
OptimizeRx Corp Surpasses Q2 2025 Estimates with 55% Revenue Increase, Achieves GAAP Net Income of $1.5M - AInvest
Stifel Nicolaus Keeps Buy Rating on OptimizeRx with $18 Price Target. - AInvest
OptimizeRx (OPRX): A High-Growth Digital Pharma Play with Explosive Q2 Earnings and Strong Balance Sheet - AInvest
Optimizerx (OPRX.O) Surges 35.67% — What’s Fueling the Intraday Spike? - AInvest
Optimizerx (OPRX.O) Surges 16%—What’s Behind the Sudden Move? - AInvest
Stifel raises Optimizerx PT to $18, maintains Buy rating. - AInvest
Earnings call transcript: OptimizeRx Q2 2025 sees EPS surprise, stock jumps - Investing.com Canada
OptimizeRx Corp (OPRX) Q2 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
OptimizeRx Reports Second Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance - The Manila Times
OptimizeRx Corp reports results for the quarter ended June 30Earnings Summary - TradingView
OptimizeRx Stock Rallies 22% After-Hours Thanks To Q2 Earnings Push - inkl
OPTIMIZERx earnings beat by $0.22, revenue topped estimates - Investing.com
OptimizeRx Q2 rev up 55% YoY to $29.2mln, raises FY25 guidance. - AInvest
Press Release: OptimizeRx Reports Second Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance - 富途牛牛
Optimizerx Corp (OPRX) 財務データ
収益
当期純利益
現金流量
EPS
Optimizerx Corp (OPRX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Silvestro Stephen L | Chief Commercial Officer |
Mar 01 '25 |
Option Exercise |
0.00 |
1,928 |
0 |
121,886 |
| Odence-Ford Marion | Chief Legal Officer & CHRO |
Mar 01 '25 |
Option Exercise |
0.00 |
771 |
0 |
70,544 |
| KLEMA CATHY | Director |
Feb 02 '25 |
Option Exercise |
0.00 |
5,109 |
0 |
11,752 |
| Odence-Ford Marion | General Counsel and CCO |
Dec 19 '24 |
Option Exercise |
0.00 |
3,927 |
0 |
28,383 |
| Silvestro Stephen L | Chief Commercial Officer |
Dec 19 '24 |
Option Exercise |
0.00 |
6,546 |
0 |
83,424 |
| Besch Doug | Chief Product Officer |
Dec 19 '24 |
Option Exercise |
0.00 |
1,964 |
0 |
12,160 |
| Stelmakh Edward | CFO/COO |
Dec 19 '24 |
Option Exercise |
0.00 |
5,237 |
0 |
38,603 |
| FEBBO WILLIAM J | CEO |
Dec 12 '24 |
Buy |
5.01 |
20,000 |
100,220 |
601,253 |
| Odence-Ford Marion | General Counsel and CCO |
Nov 08 '24 |
Option Exercise |
0.00 |
1,785 |
0 |
24,980 |
| Stelmakh Edward | CFO/COO |
Oct 11 '24 |
Option Exercise |
0.00 |
8,222 |
0 |
35,432 |
0.12%
1.30%
大文字化:
|
ボリューム (24 時間):